



# Annual Report 2022



# TABLE OF CONTENTS

## **HIGHLIGHTS**

Preface, Major Achievements, Milestones & Deliverables

**3**

## **OPEN CALLS**

Open Calls, SME Catalogue, Federated Network, Data Partners

**4**

## **INFRASTRUCTURE**

EHDEN Portal

**8**

## **RESEARCH & OUTCOMES**

Tools & Methods, Outcomes, Use Cases

**11**

## **EDUCATION & COMMUNITY**

Dissemination & Communication, Academy, Collaborations

**14**

## **LOOKING FORWARD**

Looking Forward

**17**

# PREFACE

For the EHDEN Consortium, 2022 was another remarkable year. The world started to emerge from the COVID-19 lockdown phase, and our global recognition of the impact of it continued to reverberate throughout 2022. We can be proud of EHDEN's work in responding to research priorities of the pandemic, and this is ongoing with all our collaborators. In the three pillars, Infrastructure and Network, Evidence Generation, and Community and Sustainability, EHDEN continued to progress and excel.

We have seen a rapid expansion of our Data Partner network, and certified SMEs, and are both delighted and proud to have now a unique open science community evolving across the European region. What we are seeing is a new network collaboration that will reciprocally support Data Partners clinicians and researchers collectively, and third party researchers alike, to generate evidence at scale, and at speed.

Consequently, while continuing to support completion of mapping to the OMOP common data model, we expand on the second 'E' of EHDEN, 'evidence', even more as we enter the late phase of the IMI programme. Hence, we have more use cases from characterisation through to predictive analytics to generate insights, but also demonstrate the utility of EHDEN. Meanwhile, our technical architecture has become public through the initial launch of our Data Partner catalogue and dashboards via the EHDEN Portal, and will be developed further to support the study workflow in the last, fifth year.

EHDEN is also proud of our growing Academy, with such international uptake and enrolment, supporting international training needs and the learning curve in using OMOP-mapped data and tools, skills and methods within the OHDSI framework.

Building for our future sustainability, our not-for-profit legal entity, EHDEN Foundation, will operate more in parallel to the IMI EHDEN programme from here on, as a start-up, and we are keen to ensure it has a good start in 2023, for readiness post-IMI in 2024.

We were delighted to have progressed very positively through our IMI mid-project review in the first quarter of the fourth year, with very constructive feedback. We also added a new EFPIA partner, Lundbeck to our Consortium. Lastly, thank you to the whole EHDEN Consortium, our Data Partners, SMEs, and collaborators, all who make EHDEN possible and successful.

We're looking forward to our collaborative journey through a pivotal 2023, and please do review the further detail of our progress in 2022 in this report.

## **Peter Rijnbeek**

EHDEN Coordinator  
Professor of Medical Informatics  
Erasmus Medical Center, The Netherlands

## **Nigel Hughes**

EHDEN Project Leader  
Scientific Director RWD/RWE  
Janssen R&D, Belgium

## OPEN CALLS

- The Data Selection Prioritisation Committee (DSPC) and SME Certification Committee (SMECC) have additional/new expert members.
- Data Partners and SME Open Calls are now closed after reaching a network of
  - 187 Data Partners across 29 countries.
  - 64 SMEs selected, trained, and certified in 22 countries.

## INFRASTRUCTURE

- Launch of the EHDEN Portal with free access to explore Data Partner and network dashboard of those mapped
- The single sign on, authentication and authorisation infrastructure (AAI) has been further implemented with Lifesciences AAI (formerly Elixir AAI)
- The ARACHNE node to support study implementation with Data Partners has been further developed too with EHDEN Partners and Odysseus

## EDUCATION & COMMUNITY

- EHDEN Academy has more than 3,500 participants in 70 countries and offers 17 different courses.
- EHDEN has extended its collaboration with multiple programmes and projects across IMI and Horizon Europe
- Much of the collaboration work has focused on technical, methodological, and evidence generation

## RESEARCH & OUTCOMES

- EHDEN has increased emphasis on evidence generation but also supported Data Partner engagement in research post-CDM mapping, and third-party interest in collaborating with the EHDEN Data Partner network
- An Evidence Generation Taskforce was created to have oversight of evidence generation and execution from year 4 onwards
- Collaborative study-a-thon organised by UMC with EHDEN and OHDSI on pharmacovigilance

## MAJOR ACHIEVEMENTS

Year 4 is once again a year to be proud of with regard to EHDEN and our collective achievements.

We have continued to excel in all our pillars and have met or exceeded many of our original aspirations.

Our focus continues on the sociotechnical architecture to support at-scale evidence generation, covering outputs both technical and in the domain of governance and security.


An overview of the deliverables can be found on our Zenodo page.

# 2022 OPEN CALLS

A purple-tinted background image showing a person in a business suit looking at documents on a desk.

**FOURTH SME CALL**  
(March-April 2022)

**40 APPLICATIONS**  
**17 SELECTED**

A yellow-tinted background image showing a person in a white lab coat working with a piece of equipment.

**SIXTH DATA CALL**  
(May-June 2022)

**56 APPLICATIONS**  
**32 SELECTED**

A yellow-tinted background image showing a person in a white lab coat smiling while holding a piece of equipment.

**SEVENTH DATA CALL**  
(October-November 2022)

**158 APPLICATIONS**  
**22 SELECTED**

# SME CATALOGUE

Following our four SME open calls, we now have a total of **64 SMEs** in our SME Catalogue. Each of these SMEs was selected by our independent **SME Certification Committee**, received training via the EHDEN Academy and was validated during certification meetings.

EHDEN continues to build and strengthen this community via bi-monthly update calls, an SME forum where experiences and knowledge can be shared, etc., to further reinforce this collaboration. The lessons learned during these calls are available on our [website](#).

Access the catalogue via [ehden.eu/business-directory](https://ehden.eu/business-directory)




## FEDERATED NETWORK OF DATA PARTNERS

The EHDEN project aims to collaborate with diverse institutions and data custodians across the EU, with a goal of harmonising source data to the OMOP common data model locally, within a federated network.

Following the six open calls to date, we had **187 Data Partners** from **29 different countries** which are mapping their data to the OMOP common data model. This includes a few EHDEN project partners who have also mapped their data to the OMOP CDM for use in the federated network. The seventh and final Data Partner call had an unprecedented success with 158 applications from 30 European countries.

The most up-to-date overview is available at any time via [ehden.eu/datapartners](https://ehden.eu/datapartners)



# FEDERATED NETWORK OF DATA PARTNERS

## AUSTRIA (1)

- Medical University of Vienna

## BELGIUM (14)

- AZ Damiaan Oostende
- AZ Delta
- AZ Klina
- AZ Maria Middelaes
- Icometrix
- Lynxcare
- Medaman
- Onze-Lieve-Vrouwziekenhuis Aalst-Asse-Ninove
- University Hospital Antwerp
- University MS Center
- Universitaire Ziekenhuizen KU Leuven
- UZ Brussels
- VZW AZ Groeninge
- Ziekenhuis Oost-Limburg

## BOSNIA HERZEGOVINA (1)

- E-MEDIT D.O.O. & Hospital Travnik

## BULGARIA (2)

- Technical University of Sofia
- SAT Health

## CROATIA (5)

- Clinical Hospital Dubrava
- Hierarchia d.o.o.
- IGEA d.o.o. & University Hospital Center Sestre milosrdnice
- IN2 d.o.o. & Clinical Hospital Center Osijek
- MCS Grupa d.o.o. & Health Care Center of Primorje-Gorski Kotar County

## CZECH REPUBLIC (3)

- Czech Myeloma Group
- Institute of Rheumatology
- OAKS Consulting s.r.o.

## DENMARK (2)

- Center for surgical science
- University of Southern Denmark

## ESTONIA (1)

- University of Tartu

## FINLAND (7)

- BCB Medical Ltd
- Finnish Institute for Health and Welfare (THL)
- FinRegistry
- Hospital District of Helsinki and Uusimaa
- Hospital District of Southwest Finland
- Pirkanmaa Hospital District
- Prostate Cancer Registry of South-West Finland

## FRANCE (8)

- APH de Marseille

- Bordeaux Hospital
- Bordeaux PharmacoEpi
- CegeDim Health Data
- CHU de Toulouse
- CHU de Montpellier
- Health Data Hub
- Lille University Hospital

## GEORGIA (1)

- Telavi Regional Hospital

## GERMANY (10)

- Charité - Universitätsmedizin
- European Rare Kidney Disease Registry (ERKReg)
- Krebsregister Rheinland-Pfalz
- GermanOncology
- German Cancer Society (DKG)
- Hanover Medical School
- InGef - Institute for Applied Health Research Berlin GmbH
- MS Forschungs- und Projektentwicklungs
- University Medicine Dresden
- University of Ulm, ZIBMT

## GREECE (5)

- Diagnostic & Therapeutic Center OF Athens "HYGEIA"
- Digital Health Solutions SA
- General Hospital of Kavala
- Innovative Medical Research SA
- Papageorgiou General Hospital

## HUNGARY (2)

- Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza
- National Institute of Health Insurance Fund Management Hungary
- Semmelweis University
- Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
- University of Pécs

## ITALY (26)

- AO Card. G. Panico - Center for Neurogenerative Diseases and Aging Brain
- ASL Roma 1
- ASST Papa Giovanni XXIII
- ATS Bergamo
- AUSL Reggio Emilia
- Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
- Azienda Ospedaliera Universitaria Integrata Verona
- Azienda Ospedaliera Universitaria San Luigi Gonzaga
- Azienda Policlinico Universitaria di Modena
- Bambino Gesù Children's Hospital
- Basilicata Cancer Registry

- Casa di Cura Privata del Policlinico (CCPP)
- Fondazione Casa Sollievo della Sofferenza
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Fondazione IRCCS Istituto Neurologico Carlo Besta
- Fondazione IRCCS Policlinico San Matteo

- Fondazione Istituto Nazionale de Tumori
- Fondazione Poliambulanza Istituto Ospedaliero
- Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica (FTGM)
- INSPIRE
- ISMETT
- Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli"
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Santa Orsola
- IRCCS Policlinico San Donato
- SIMG
- University Hospital of Parma

## IRELAND (1)

- Trinity St James's Cancer Institute

## ISRAEL (4)

- Assuta medical Centers
- Bnai Zion Medical Center
- Hadassah OBGYN
- The Directorate of Government Medical Centers at the Israeli Ministry of Health

## LUXEMBOURG (1)

- Registre National du Cancer du Luxembourg

## MONTENEGRO (1)

- Clinical Center of Montenegro

## NORWAY (2)

- University of Oslo
- The Norwegian Cancer Registry

## PORTUGAL (11)

- APDP
- Centro Academico Clínico Egas Moniz Health Alliance
- Centro Clínico Académico – Braga (2CA-Braga)
- Centro Hospitalar Universitário de Coimbra
- CUF
- Hospital da Luz Learning Health
- Hospital Distrital de Santarém
- Hospital do Espírito Santo de Évora
- Instituto de Medicina Molecular
- Registo Portugues de Doentes

- Reumaticos
- Unidade Local de Saúde de Matosinhos

## SERBIA (4)

- Clinical Center of Serbia
- Clinical Centre of Nis
- Clinical Hospital Center Zvezdara
- Primary Healthcare Center Zen

## SPAIN (27)

- Biocruces Bizkaia Health Research Institute Consellería de Sanidade
- Consorci Corporació Sanitària Parc Taulí
- FISABIO-HSRU
- Fundació Institut d'Investigació Sanitària Illes Balears
- Fundación de Investigación Biomédica del Hospital Universitario 12 de Octubre
- Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE)
- Fundación para la Investigación e Innovación Biosanitaria en Atención Primaria (FIIBAP)
- Hospital sant Joan de Déu
- INCLIVA
- Instituto Aragonés de Ciencias de la Salud (IACS)
- Institut Català d'Oncologia
- Institut Hospital del Mar Investigacions Mèdiques Marina Salud S.A.
- Parc Salut Mar Barcelona
- Parc Sanitari Sant Joan de Déu
- Quironsalud
- Research Institute - Hospital de la Santa Creu i Sant Pau
- Rioja Salud
- Servei Català de la Salut
- Servicio Cántabro de Salud and IDIVAL
- Servicio Madrileño de Salud (SERMAS)
- Servicio Navarro de Salud-Osasunbidea
- Spanish Agency of Medicines and Medical Devices
- The Information System for Research in Primary Care
- Vall d'Hebrón Hospital Marina Salud S.A.
- Virgen Macarena University Hospital

## SWITZERLAND (5)

- CancerDataNet GmbH
- Center for Primary Care and Public Health (Unisanté)
- Geneva Cancer Registry
- Institute of Social and Preventive Medicine, University of Bern

- University Hospital Geneva

## SWEDEN (4)

- Gothenburg University
- MEB Karolinska Institutet
- Stockholm CREATinine Measurements Project
- SWIBREG

## THE NETHERLANDS (10)

- Amsterdam UMC
- EBMT
- ECRAID and UMCU
- Equipe Zorgbedrijven
- IKNL
- Lage Landen Foundation
- NICE Foundation
- Stichting VUMC
- STIZON
- VieCuri Medisch Centrum

## TURKEY (3)


- Bayindir Healthcare Group
- Istanbul University - Faculty of Medicine
- IUC Cerrahpaşa TIP Fakültesi

## UKRAINE (1)

- National Cancer Institute

## UNITED KINGDOM (22)

- Akrivia Health
- Barts Health NHS Trust
- Clinical Practice Research Datalink
- Connected Bradford
- CVD-COVID-UK/COVID-IMPACT
- Discover-NOW
- Genomics England
- GOSH
- Harvey Walsh Ltd
- Health Informatics Centre
- King's College London
- Leeds Teaching Hospitals
- LancashireTeaching Hospitals NHS Foundation Trust
- National Joint Registry
- Optimum Patient Care
- Queen Mary University of London
- Royal College of General Practitioners Research and Surveillance Centre
- SAIL Databank
- UK National Neonatal Research Database
- University College London
- University College London Hospitals
- University of Edinburgh



# OF DATA PARTNERS

# EHDEN PORTAL

The EHDEN technical framework comprises the entire set of technical constructs, i.e. applications and their interoperability, including security setup within the context of the IMI EHDEN Project.

The **EHDEN Portal** has been publicly released on June 24th 2022, making it available to the wider community. Currently, it provides metadata of 80 healthcare databases in the database catalogue and data exports based on full conversion into the OMOP CDM from **64** Data Partners that are available in the network dashboard.

Since its launch, more than **500 active users** have been registered and more than **9,000 new users** have visited the Portal.

The image displays two screenshots from the EHDEN Portal. The left screenshot shows the 'Welcome to the EHDEN Portal' page, which includes a navigation sidebar on the left with options like HOME, CATALOGUE, DASHBOARD, ACADEMY, EHDEN, PUBLICATIONS, STATUS, and MANAGE. The main content area features a welcome message and six key service tiles: Database Catalogue, Network Dashboards, EHDEN Academy, Publications, ARACHNE, ATLAS, and Service Desk. The right screenshot shows the 'Network Dashboard' with filters for Country, Database Type, and Data Source. It displays summary statistics: 19 Countries, 64 Data Sources, and 153M Patients. Two charts are visible: 'Patients by Country' (a bar chart) and 'Database Types per Country' (a heatmap).

# TOOLS AND METHOD DEVELOPMENT

In the course of year four of EHDEN, an ever growing number of data sources have been added to the EHDEN Portal. A rich set of (meta) data was added to the database catalogue, allowing researchers to identify and leverage relevant data sets for the generation of reliable evidence. Sixty-four healthcare databases from Data Partners are fully converted to the OMOP CDM and available for the Network Dashboard

Further development of ARACHNE tool that enables an approval workflow controlled by the Data Partner for participation, execution and approval of studies

The main functionalities are profiling of the source data (White Rabbit), creating mapping documentation (Rabbit in a Hat) and mapping source terms to the OMOP standard vocabulary (Usagi)


ELIXIR AAI (currently called Life science Login) has been implemented as a Single Sign On service.

A few new database platforms have been added to the OHDSI tools stack including Apache Spark, Snowflake and Azure Synapse Analytics Dedicated extending the already broad variety of OMOP CDM data source dialects

# TIMELINE EHDEN PORTAL

The central component of the EHDEN infrastructure is the EHDEN Portal. After making the first version of the portal available to the public in June 2022, we are currently working on the finalization of the version 2 (see here to the right).

For year 5, the focus will be on enabling the operationalisation of the EHDEN infrastructure and further optimise the support of end-to-end evidence generation using the OMOP CDM. The focus will be on the integration of the components technically and from a process perspective, especially with an eye on the sustainability of the set up for the time post-EHDEN.



**Version 1 (AVAILABLE NOW):**

- View the metadata on 67 of EHDEN Data Partners
- Navigage through the network dashboards covering > 40 million patients/35 databases
- Understand which databases are covering which diseases/ drugs / procedures

**Version 2 (anticipated availability by YE '22):**

Perform study feasibility assessments across the EHDEN network

- Determine the size of the eligible patient population across the network for a research question
- Understand the variables present for the cohort(s) of interest

**Version 3 (anticipated availability by YE '23):**

Full study execution including sharing of results in interactive web applications

## USE CASE 3 SIGNAL DETECTION IN LONGITUDINAL OBSERVATIONAL DATA

This study had more than thirty colleagues from the Uppsala Monitoring Centre (UMC), EHDEN, DARWIN EU, and EHDEN Data Partners come together in Uppsala, Sweden to take part in the UMC/EHDEN pharmacovigilance evidence-a-thon.

The scope of the evidence-a-thon involved all mature products with generic manufacturers, and sixteen outcomes that had previously been phenotyped within the OHDSI community as part of its COVID-19 research.

The event made it clear that we currently have the ability to efficiently generate actionable real-world evidence to support preliminary signal assessment using our existing tools, data, and infrastructure.

The week's experience also inspired ideas for how to develop new open-source analytic solutions that can support the pharmacovigilance use case even further.



*Above: group photo of the e-thon participants. The group is composed of colleagues from Uppsala Monitoring Centre (UMC), EHDEN, DARWIN EU, and EHDEN Data Partners.*

# EVIDENCE GENERATION

In addition to the originally planned studies, the study planning and execution (evidence generation) work has increased this year after the approval of the new task (T1.8). An Evidence Generation Task Force was created to evaluate internal proposals for new studies.

**29 requests** were received and a methodology created to prioritise the **4 studies for execution**. WP1 is co-leading or supporting the planning and execution of these 4 additional studies with the use of the Evidence Generation Fund

## Characterisation of Heavy Menstrual Bleeding

This is a study led by Bayer, WP1 co-lead, aiming to describe the presentation of heavy menstrual bleeding. Bayer has led the design of the study and the selection of suitable Data Partners within the EHDEN network. UOXF is helping with the liaison with the selected data partners, and with the planning of analyses and dissemination activities.

1

## Expansion of the CDM with a pregnancy extension table

Led by one of the EHDEN Data Partners (SIDIAP), this study has resulted in the creation of an extension table to enable future studies on pregnancy and neonatal epidemiology. Currently, SIDIAP, UOXF and an additional EHDEN DP (University of Oslo) are testing the resulting table in some of the existing datasets. This study should be completed during the first half of 2023.

2

## Extrapolation of survival data for Health Technology Assessments

Led by NICE and UOXF and in close collaboration with WP2, tools have been developed for the extrapolation of survival data for several cancers. More detail is provided as part of WP2 activities.

3

## Long COVID

Led by UOXF, this study is describing the different presentations of persistent COVID amongst patients diagnosed in the community and in hospital settings. Phenotypes have been developed for all 25 key symptoms identified in the WHO definition of long COVID, and for key sequelae/complications including thromboembolic events. The study is currently being conducted at three EHDEN Data Partners, and will be rolled out by invitation to many others during Q1 and will conclude in the form of a Study-A-Thon in Q2 2023.

4



# OUR SCIENTIFIC OUTPUT IN YEAR FOUR

## A SAMPLE OF SOME OF OUR PUBLICATIONS

- Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network (*BMC Med Res Methodol*)
- Learning patient-level prediction models across multiple healthcare databases: evaluation of ensembles for increasing model transportability (*BMC Med Res Methodol*)
- Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis (*BMJ*)
- Transforming and evaluating the UK Biobank to the OMOP Common Data Model for COVID-19 research and beyond (*JAMIA*)
- Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations (*Drug Safety*)

## EVENTS

- > 20 posters for the OHDSI European Symposium (June 2022)
- invited speakers in ~10 International Conferences

## MORE INFO

- Visit our [EHDEN Zenodo page](#) for all of our latest publications
- [Pharmacovigilance evidence-a-thon](#)
- [EHDEN Website newsposts](#)

## DISSEMINATION

EHDEN aims to be at the forefront of open science, making healthcare data more accessible for research. Our dissemination activities reflect this vision and as such, all our papers, preprints and public deliverables are available via the [EHDEN Zenodo page](#).

## COMMUNICATION

Our communication aims at building an open science community that will endure and use the project outcomes long after the project has ended. This has resulted in an average of 18,000 visitors to the [EHDEN website](#) each month and a steady increase in followers on [Twitter](#) and [LinkedIn](#). A complete overview of all newposts, newsletters, webinars, podcasts, videos, etc., can be accessed via our website.

We are also proud of our "[Voice of EHDEN](#)" podcast and the new limited series around "[Ethics, Legal and Social Implications](#)" launched in October 2022. These podcasts bring together a diverse range of experts to discuss key aspects of working with real world data in large scale observational research, network studies and building 21st century architecture.




# EHDEN ACADEMY

The **EHDEN Academy** has grown to be a significant educational and collaborative resource for EHDEN, OHDSI and the global community with regard to training and upskilling.

At the end of the fourth year, **over 3,500 users** from **70 countries** have started their learning journey in the Academy.

With **17 courses** currently available, the Academy continues to update its curriculum and number of expert trainers, with specific focus on more HTA and regulatory science trainings planned for launch in year five.



# COLLABORATIONS

- EHDEN has extended its collaboration with multiple programmes and projects across **IMI** and **Horizon Europe**
- Much of the collaboration work has focused on **technical, methodological, and evidence generation**, in particular:
  - Mapping source data to the OMOP common data model
  - Data quality dashboard and source data evaluation
  - Evidence generation and study collaboration
  - Sustainability path
- The **EHDEN Academy** entered into a collaboration and co-promotion with **HDR UK, Institute for Innovation through Health Data (i~HD)** and the **GetReal Institute** academies
- EHDEN continues to work symbiotically with **OHDSI** across multiple aspects of combined interest, as well as with **OHDSI Europe** specifically, on the annual meeting and national node development

# LOOKING FORWARD

Based on the foundation of our first four years, the coming 5th and final full IMI year of EHDEN in 2023 will be pivotal as EHDEN transitions beyond IMI to a sustainable legal entity: the EHDEN Foundation. All our pillars and work will have to convert into the sustainable open science community, network architecture, at-scale evidence generation, training, certification and support, and the overall service offering of EHDEN longer term.

We will look to the completion of our next phase of the Portal development to facilitate the study workflow, expansion of our evidence generation, in particular large-scale studies across our Data Partner network. And we look forward to transitioning aspects of the project, such as the EHDEN Academy, to the EHDEN Foundation through 2023.

Critical for EHDEN is the ongoing support of our Data Partners and SMEs, especially following their mapping of source data to the OMOP common data model and being truly 'research ready'. It is imperative that Data Partners benefit first prior to third parties with their own research, audit, and analytical needs.

Working to the second 'E' of EHDEN, evidence, we will be extending our studies, study-a-thons, and a large-scale study across the network, further demonstrating the impact of the EHDEN network.

Ultimately, we will be in 'dress rehearsal' mode for operating within our EHDEN Foundation to prepare the ground for being post-IMI in 2024.





The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

